SEVERAL new drugs for the treatment of depression have been introduced over the past several years. Among them is imipramine hydrochloride (Tofrānil), chemically 5-(3-dimethylaminopropyl)-10, 11-dihydro-5 H-dibenz [b, f] azepine hydrochloride. The effectiveness of this drug in the treatment of depression was initially described by Kuhn,1 and later confirmed by others.2-3 The mechanism of action of the drug has not been established, but structurally it is similar to drugs with a phenothiazine base.
During the treatment of several mildly diabetic patients who were also depressed, we observed a diminution of glycosuria concomitant with the administration of imipramine, with a return to premedication levels of glycosuria when use of the imipramine was discontinued. We have now noted this effect in 5 subjects, 4 of whom were depressed, while the 5th was not. These clinical observations seemed sufficiently important to warrant further study, especially since it is only in the past
Kaplan SM, Mass JW, Pixley JM, Ross WD. Use of Imipramine in DiabeticsEffects on Glycosuria and Blood Sugar Levels. JAMA. 1960;174(5):511–517. doi:10.1001/jama.1960.63030050009013
Customize your JAMA Network experience by selecting one or more topics from the list below.